These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 24403465

  • 1. Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.
    Nakano M, Kusaba H, Makiyama A, Ariyama H, Arita S, Oda H, Esaki T, Takayoshi K, Uchino K, Tamura S, Kumagai H, Iwama E, Shirakawa T, Mitsugi K, Takaishi S, Akashi K, Baba E.
    Anticancer Res; 2014 Jan; 34(1):215-20. PubMed ID: 24403465
    [Abstract] [Full Text] [Related]

  • 2. [A case of malignant peritoneal mesothelioma diagnosed with laparoscopic biopsy].
    Yagi Y, Maeda T, Yoshimitsu Y, Sakuma H.
    Gan To Kagaku Ryoho; 2014 Aug; 41(8):995-7. PubMed ID: 25132032
    [Abstract] [Full Text] [Related]

  • 3. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
    Chen D, Li X, Zhao H, Fu Y, Yao F, Hu J, Du N.
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
    [Abstract] [Full Text] [Related]

  • 4. The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.
    Kim ST, Park JY, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH.
    Jpn J Clin Oncol; 2010 Nov; 40(11):1031-6. PubMed ID: 20534685
    [Abstract] [Full Text] [Related]

  • 5. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
    Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, Shimokawa M, Seto T, Ichinose Y.
    Int J Clin Oncol; 2014 Aug; 19(4):601-6. PubMed ID: 24158772
    [Abstract] [Full Text] [Related]

  • 6. [A case of malignant peritoneal mesothelioma with the epithelioid histological type, successfully treated with pemetrexed plus cisplatin].
    Kobayashi M, Moriwaki T, Ochi D, Saito R, Kobayashi K, Sugaya A, Akutsu D, Hamano Y, Imanishi M, Yamamoto Y, Yamada T, Nakano N, Sugano M, Hara K, Hyodo I.
    Gan To Kagaku Ryoho; 2014 Mar; 41(3):361-4. PubMed ID: 24743284
    [Abstract] [Full Text] [Related]

  • 7. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
    Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA.
    Clin Cancer Res; 2014 Dec 01; 20(23):5927-36. PubMed ID: 25231400
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study.
    Kitadai R, Shimoi T, Sudo K, Noguchi E, Nagata Y, Sawada R, Takashima A, Boku N, Yonemori K.
    BMC Cancer; 2021 Mar 20; 21(1):294. PubMed ID: 33743636
    [Abstract] [Full Text] [Related]

  • 9. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
    Habib EE, Fahmy ES.
    Clin Transl Oncol; 2013 Nov 20; 15(11):965-8. PubMed ID: 23408040
    [Abstract] [Full Text] [Related]

  • 10. Malignant peritoneal mesothelioma in a child: chemotherapy with gemcitabine and platinum was effective for the disease unresponsive to other treatments.
    Kobayashi S, Waragai T, Sano H, Mochizuki K, Akaihata M, Ohara Y, Hosoya M, Kikuta A.
    Anticancer Drugs; 2014 Oct 20; 25(9):1102-5. PubMed ID: 25010395
    [Abstract] [Full Text] [Related]

  • 11. Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.
    Christoph DC, Asuncion BR, Mascaux C, Tran C, Lu X, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Neumann V, Hepp R, Welter S, Stamatis G, Tannapfel A, Schuler M, Eberhardt WE, Hirsch FR.
    J Thorac Oncol; 2012 Sep 20; 7(9):1440-8. PubMed ID: 22895141
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.
    Nagata Y, Sawada R, Takashima A, Shoji H, Honma Y, Iwasa S, Amano K, Kato K, Hamaguchi T, Shimada Y, Saruta M, Boku N.
    Jpn J Clin Oncol; 2019 Dec 18; 49(11):1004-1008. PubMed ID: 31287877
    [Abstract] [Full Text] [Related]

  • 13. [Clinical features of patients with malignant peritoneal mesothelioma initially presenting as a local inflammation].
    Song H, Zheng G, Wei S, Yang Y, Wei X.
    Zhonghua Zhong Liu Za Zhi; 2014 Apr 18; 36(4):312-3. PubMed ID: 24989921
    [No Abstract] [Full Text] [Related]

  • 14. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
    Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, He X, Hall R, Kawabe T, Sharma S.
    Lung Cancer; 2014 Sep 18; 85(3):429-34. PubMed ID: 25047675
    [Abstract] [Full Text] [Related]

  • 15. Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single institution experience.
    Lainakis G, Zagouri F, Kastritis E, Sergentanis TN, Bozas G, Dimopoulos MA, Papadimitriou CA.
    Tumori; 2011 Sep 18; 97(1):25-9. PubMed ID: 21528659
    [Abstract] [Full Text] [Related]

  • 16. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
    Tsao AS, Harun N, Lee JJ, Heymach J, Pisters K, Hong WK, Fujimoto J, Wistuba I.
    Clin Lung Cancer; 2014 May 18; 15(3):197-201. PubMed ID: 24492162
    [Abstract] [Full Text] [Related]

  • 17. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I.
    Cancer; 2014 Nov 01; 120(21):3311-9. PubMed ID: 24989332
    [Abstract] [Full Text] [Related]

  • 18. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
    Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, Pavlakis N, Nowak AK, Custers FL, Schouwink JH, Gans SJ, Groen HJ, Strankinga WF, Baas P.
    Lancet Oncol; 2013 May 01; 14(6):543-51. PubMed ID: 23583604
    [Abstract] [Full Text] [Related]

  • 19. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
    Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, Mencoboni M, Planchard D, Chella A, Crinò L, Krzakowski M, Rüssel J, Maconi A, Gianoncelli L, Grosso F.
    Lancet Oncol; 2019 Dec 01; 20(12):1702-1709. PubMed ID: 31628016
    [Abstract] [Full Text] [Related]

  • 20. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
    Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C.
    J Thorac Oncol; 2008 Jul 01; 3(7):756-63. PubMed ID: 18594322
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.